All In Biotech

Drug Trial Radar · NCT06598397

Using Multiphase Optimization Strategy (MOST) to Optimize a Cost-effective, Sustainable and Scalable Smoking Cessation Package for Smokers in HIV Clinical Care

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 500 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

500

Planned (sponsor's estimate)

Start

Oct 18, 2024

Primary completion

Jun 30, 2028

Study completion Jun 30, 2028

Sponsor

Lead sponsor
New York UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Factorial
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study's long-term goal is to improve clinical outcomes among smokers living with HIV (SLWH) by providing smoking cessation interventions in HIV clinical care that will increase the chances of quitting smoking, limits costs and burden on staff and reach many smokers living with HIV.

Conditions

  • Human Immunodeficiency Virus (HIV)
  • Smoking Cessation

Interventions

  • Motivational Interviewing (MI) CounselingBehavioral

    Six sessions of phone counseling over 10-12 weeks with MI counselor trained in motivational interviewing and tobacco use treatment.

  • Peer MentoringBehavioral

    Eight sessions of informal counseling with an experienced peer former smoker living with HIV to model healthy behavior and provide practical advice and tips for quitting based on their lived experience.

  • Skills-based Text MessagingBehavioral

    NCI's 8-week text messaging smoking cessation program, smokefreeTXT.gov.

  • Combination NRTDrug

    If they smoke 10 or more cigarettes per day (CPD), participants will receive 2 weeks of 21 mg patches, 2 weeks of 14 mg patches and 2 weeks of 7 mg patches; if they smoke less than 10 CPD, participants will receive 4 weeks of 14 mg patches and 2 weeks of 7 mg patches. Participants will receive either 2 or 4 mg of nicotine lozenges for a total of up to 20 lozenges per day.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Biochemically-validated 7-day point prevalence smoking abstinence among SLWH in HIV clinical careTime frame: 32 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • New York University School of Global Public Health

    New York, New York · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.